^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Vulvar Cancer

    1d
    AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors (clinicaltrials.gov)
    P1, N=144, Not yet recruiting, Avacta Life Sciences Ltd
    New P1 trial • First-in-human
    5d
    Electrochemotherapy for Recurrent Vulvar Cancer (clinicaltrials.gov)
    P2, N=13, Recruiting, Institute of Oncology Ljubljana
    New P2 trial
    |
    bleomycin
    8d
    Oral Administration of Itraconazole Induces M1 Polarization of Tumor-associated Macrophages in Gynecological Cancer. (PubMed, In Vivo)
    ITZ treatment was associated with increased infiltration of M1-like TAMs in cancer tissues, suggesting an immunomodulatory effect. These findings support further investigation of ITZ as a potential adjunct in cancer therapy.
    Journal
    |
    CD163 (CD163 Molecule) • CD86 (CD86 Molecule)
    |
    itraconazole
    8d
    MOST-CIRCUIT: Combination Immunotherapy in Rare Cancers Under InvesTigation (clinicaltrials.gov)
    P2, N=240, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Trial completion date: Mar 2028 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    9d
    Major Advances in Gynecologic Oncology in 2025: Systematic Review and Synthesis of Conference and Published Evidence. (PubMed, Biomedicines)
    (2) In ovarian cancer, the ENGOT-ov65/KEYNOTE-B96 trial demonstrated the first statistically significant overall survival improvement with an immune checkpoint inhibitor in platinum-resistant recurrent disease, establishing pembrolizumab plus weekly paclitaxel as a new standard of care. (5) The extensive circulating tumor DNA analysis from the CALLA trial provided crucial insights into biomarker dynamics in cervical cancer. The convergence of high-impact data from 2025 established multiple new standards of care, emphasizing biomarker-driven approaches, immunotherapy integration across disease stages, and novel mechanisms to overcome resistance, while highlighting challenges in treatment sequencing and global access.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CDH6 (Cadherin 6)
    |
    Keytruda (pembrolizumab) • paclitaxel
    9d
    Pre-ANVU: Feasibility of Groin Ultrasound to Predict Groin Lymph Node Involvement in Patients with Histologically Proven Vulvar Cancer (ACTRN12622000886785)
    P=N/A, N=65, Recruiting, University of Queensland | N=100 --> 65
    Enrollment change
    9d
    Myxoid Solitary Fibrous Tumor of the Vulva: A Diagnostic Pitfall. (PubMed, Int J Gynecol Pathol)
    Immunohistochemistry showed diffuse nuclear STAT6 and CD34 positivity, and molecular analysis confirmed a NAB2:::STAT6 fusion. This case highlights the diagnostic pitfalls associated with myxoid change in vulvar mesenchymal tumors and underscores the importance of immunohistochemical and molecular confirmation.
    Journal
    |
    CD34 (CD34 molecule) • STAT6 (Signal transducer and activator of transcription 6) • NAB2 (NGFI-A Binding Protein 2)
    9d
    Metastatic Granular Cell Tumor of the Vulva With CHEK2 Mutation: A Case Report and Molecular Insights. (PubMed, Int J Gynecol Pathol)
    Our findings underscore the importance of integrating molecular profiling into the diagnostic and prognostic workup of GCTs and raise the question about the potential role of CHEK2 alterations as additional molecular determinants of aggressiveness beyond conventional histology. Long-term follow-up is warranted given the unpredictable clinical behavior of malignant GCTs.
    Journal
    |
    MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • CHEK2 (Checkpoint kinase 2) • CD68 (CD68 Molecule)
    |
    HRD • CHEK2 mutation
    13d
    Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2nMITO VULVA-01 study. (2023-509180-24-00)
    P1/2, N=80, Recruiting, IRCCS Istituto Nazionale Tumori Fondazione Pascale | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    15d
    A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    Tyvyt (sintilimab) • Yutuo (zimberelimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    15d
    NODE (groiN ultrasOunD cancEr) (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Queensland Centre for Gynaecological Cancer | Trial completion date: Mar 2028 --> Dec 2027 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    18d
    Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2nMITO VULVA-01 study. (2023-509180-24-00)
    P1/2, N=80, Not yet recruiting, IRCCS Istituto Nazionale Tumori Fondazione Pascale
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)